Hyperthermic Intraperitoneal Chemotherapy in Improving Quality of Life in Patients with Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• Patients must have histologically or cytologically confirmed non-mucinous, epithelial stage 3 or 4 carcinoma of the ovary, fallopian tube or peritoneum
• Patients must not have received treatment for another malignancy within 3 years of enrollment
• Patients must have received at least 3 but not more than 6 cycles of carboplatin-doublet based IV neoadjuvant chemotherapy and achieved at least stable disease (radiographically confirmed) at the conclusion of this therapy
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Absolute neutrophil count >= 1,500/mcL (within 30 days of registration)
• Platelets >= 75,000/mcL (within 30 days of registration)
• Total bilirubin =< 1.5 mg/dL (within 30 days of registration)
• Creatinine clearance >= 50 mL/min (within 30 days of registration)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal (within 30 days of registration)
• Alkaline phosphatase =< 3 x institutional upper limit of normal (within 30 days of registration)
• The effects of HIPEC on the developing human fetus are unknown; for this reason, and because carboplatin doublet therapy consists of pregnancy category D agents, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document

Exclusion Criteria

• Patients may not be receiving any other investigational agents
• Patients with extra-abdominal metastatic disease
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin doublet agents
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study because carboplatin doublet therapy consists of pregnancy category D agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with carboplatin doublet therapy, breastfeeding should be discontinued
• Men are excluded from participation due to the site-specific nature of the disease being studied